Education
About Us
Working with TipRanks
Follow Us
Fulcrum Therapeutics (FULC)
NASDAQ:FULC
Earnings Data
Report Date
May 19, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.29Last Year’s EPS
-0.43Same Quarter Last Year
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 25, 2025
|% Change Since: -2.97%
|Next Earnings Date:May 19, 2025
Earnings Call Sentiment|Neutral
The earnings call highlights positive financial management with a strengthened cash position and reduced net loss, alongside promising progress in the sickle cell disease program. However, the lack of collaboration revenue in Q4 and restructuring costs present challenges. The sentiment is balanced with meaningful progress and ongoing challenges.Company Guidance
During the Fulcrum Therapeutics conference call discussing their financial results and business updates, several key metrics and guidance points were highlighted. The company ended 2024 with a strong cash position of $241 million, which, combined with existing cash, cash equivalents, and marketable securities, is expected to fund operations through at least 2027. For 2025, Fulcrum anticipates a cash burn of $55-65 million. Their lead program, pociredir, is in development for sickle cell disease, with data readouts from the 12 mg cohort expected in mid-2025 and the 20 mg cohort by year-end. Research and development expenses for 2024 were $63.4 million, a reduction from the previous year due to cost-sharing reimbursements and discontinued programs. The company also reported a significant increase in collaboration revenue in 2024, primarily due to an $80 million upfront license payment from Sanofi. Overall, Fulcrum's strategic focus remains on advancing their pipeline in benign hematological conditions, alongside potential BD opportunities and preclinical explorations in oncology.Strong Cash Position and Financial Health
Fulcrum ended 2024 with cash, cash equivalents, and marketable securities of $241 million, an increase from $236.2 million as of December 31, 2023, due to an $80 million upfront payment from Sanofi. This positions the company to fund operations into 2027.
Significant Reduction in Net Loss
The net loss for the year ended December 31, 2024, was $9.7 million, a substantial decrease from $97.3 million for the same period in 2023, indicating improved financial management and reduced expenses.
Progress in Sickle Cell Disease Program
The PIONEER trial for pociredir, an oral HbF inducer for sickle cell disease, shows promising progress with enrollment continuing and data from the 12 mg cohort expected mid-2025.
Reduction in Operating Expenses
Research and development expenses decreased by $8.4 million and general and administrative expenses decreased by $5.3 million in 2024 compared to 2023, primarily due to workforce reduction and cost-sharing reimbursements.
---
FULC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
FULC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 25, 2025 | $3.70 | $3.70 | 0.00% |
| Nov 13, 2024 | $3.64 | $3.56 | -2.20% |
| Jul 31, 2024 | $8.41 | $9.28 | +10.34% |
| May 13, 2024 | $7.47 | $7.35 | -1.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Fulcrum Therapeutics (FULC) report earnings?
Fulcrum Therapeutics (FULC) is schdueled to report earning on May 19, 2025, TBA Not Confirmed.
What is Fulcrum Therapeutics (FULC) earnings time?
Fulcrum Therapeutics (FULC) earnings time is at May 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FULC EPS forecast?
FULC EPS forecast for the fiscal quarter 2025 (Q1) is -0.29.
---